Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

20156,162 citationsJournal Articlebronze Open Access

Authors

Edward B. Garon · University of California, Los Angeles

Naiyer A. Rizvi · Columbia University

Rina Hui · The University of Sydney

Natasha B. Leighl · Princess Margaret Cancer Centre

Ani Sarkis Balmanoukian · Angeles Clinic and Research Institute

Joseph P. Eder · Yale University

Amita Patnaik

Abstract

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 ClinicalTrials.gov number, NCT01295827.).

Topics & Keywords

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 21, pp. 2018-2028

DOI: 10.1056/nejmoa1501824

Field-Weighted Citation Impact: 304.23